Euro-backing for Berlin breast biomarker project
Tuesday February 21st, 2012
A major new European project to develop personalised breast cancer therapy is to be led from Berlin, Germany, it has been announced.
Some six million Euros from the European Commission is supporting the three year project, dubbed Responsify.
Developers at Charité Universitätsmedizin Berlin want to use biomarkers to bring forward the start of drug treatment for the cancer.
Their aim is to begin treatment before women undergo surgery - minimising tumours before surgeons conduct removal.
The project also involved the Stockholm Karolinska Institutet in Sweden, the Institut Gustave Roussy in France and University College London, UK.
Researcher Professor Carsten Denkert said: "The advantage of neoadjuvant therapy is that the effective response of the therapy on the tumour is immediately visible.
"This is why we are better able to judge which biomarkers are appropriate for directing the therapy."
Tags: Cancer | Europe | Women’s Health & Gynaecology
Printer friendly page